In Ireland, KESIMPTA® (ofatumumab) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.¹

For full safety information, please refer to the KESIMPTA Summary of Product Characteristics.

KESIMPTA downloadable resources

This selection of resources is designed for healthcare professionals (HCPs) to support patients with RMS throughout their KESIMPTA journey.

You can download these materials and share them with your healthcare team.

Adminstering KESIMPTA with the Sensoready® pen

Real-World MS Care - KESIMPTA: Practical Considerations

Getting started with KESIMPTA®

PDF

HCP, healthcare professional; RMS, relapsing forms of multiple sclerosis.

References

KESIMPTA (ofatumumab) Summary of Product Characteristics. Available at www.medicines.ie.

Safety profile

ASCLEPIOS and ALITHIOS clinical trials and efficacy

Dosing and administration

IE11499638 | July 2026

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance at www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.